Skip to content

Press Releases

Ansa Biotechnologies Expands Successful Early Access Program for Complex DNA Synthesis

    Ansa Biotechnologies is expanding its early access program for its complex DNA synthesis services. More customers around the world will now be able to take advantage of the company’s innovative enzymatic DNA synthesis technology to accelerate innovation in healthcare, life science research, and other industries powered by synthetic DNA. View the press release.

    Ansa Biotechnologies Appoints Jason T. Gammack as CEO

      Gammack is joining the company as it completes its early access program and prepares for a full commercial launch of its rapid enzymatic synthesis for complex clonal genes and gene fragments. Founding CEO Dan Lin-Arlow, PhD, will remain with the company and transition to a new position as chief scientific officer. View the press release.

      Ansa Biotechnologies Announces First Shipments of Complex Clonal DNA Sequences to Customers in its Early Access Program

        Ansa successfully synthesized and delivered challenging promoter sequences with high GC and AT content to its first Early Access customer, Enoda, which were used to engineer gene expression. Ansa’s proprietary next-generation enzymatic DNA synthesis technology overcomes the limitations of traditional methods, giving scientists access to accurate complex DNA, quickly and reliably. View the press release.

        Ansa Biotechnologies partners with TeselaGen Biotechnology to enable commercial production of DNA products

          “Ansa Biotechnologies Inc., the company developing a new way to make DNA using enzymes, is announcing a partnership with TeselaGen Biotechnology Inc., the company developing an integrated enterprise software operating system for designing, building, and optimizing biological and biochemical products. The partnership will bring a broad set of tools to Ansa Biotechnologies that will bolster R&D workflows and enable early-stage… 

          Ansa Biotechnologies Raises $9.2 Million in Combined Seed and Pre-Seed Financing

            “Ansa Biotechnologies today announced that it has raised $7.9 million in an oversubscribed Seed round of funding led by Horizons Ventures, with participation from Mubadala Capital, Humboldt Fund, and additional investors. Combined with a Pre-Seed round raised in December 2018 led by Fifty Years, the company has raised $9.2 million to date.…” View the press release.